Prediabetes Market Size, Share & Industry Analysis, By Drug Class (Biguanide, Thiazolidinediones, Glucagon-like Peptide-1 Agonists (GLP-1), DPP-4 Inhibitors), By Age Group (Children, Adults, Elderly), and Regional Forecast, 2026-2034

The global prediabetes market size was valued at USD 357.86 billion in 2025. The market is projected to grow from USD 397.46 billion in 2026 to USD 920.23 billion by 2034, exhibiting a CAGR of 11.06% during the forecast period.

The prediabetes market is witnessing substantial expansion due to the growing prevalence of impaired glucose regulation, increasing obesity rates, sedentary lifestyles, and rising awareness regarding early diabetes prevention. Healthcare systems are focusing on identifying at-risk populations before progression to type 2 diabetes, creating strong demand for screening programs, pharmacological interventions, digital health platforms, and preventive care solutions. The prediabetes market report highlights increasing adoption of glucose monitoring technologies, personalized nutrition programs, and lifestyle management therapies. Pharmaceutical companies are expanding research activities targeting metabolic disorders, while healthcare providers emphasize early intervention strategies. Growing investments in preventive medicine continue to shape the prediabetes market size, prediabetes market trends, and overall prediabetes industry analysis.

The United States represents the largest contributor to the prediabetes market due to widespread screening initiatives, advanced healthcare infrastructure, and a significant population affected by metabolic disorders. Millions of adults are identified with elevated blood glucose levels that remain below the diabetes threshold, driving demand for preventive healthcare services. Healthcare organizations increasingly integrate digital coaching, remote monitoring, and prescription-based interventions into patient management programs. The prediabetes market research report indicates that pharmacies, hospitals, and primary care networks are expanding early detection efforts. Strong clinical research activity, extensive insurance coverage for preventive care, and growing consumer awareness continue supporting the USA prediabetes market outlook and prediabetes market opportunities.

Prediabetes Market Key Takeaways

 Global Market Size & Forecast

• 2025 Market Size: USD 357.86 Billion
• 2026 Market Size: USD 397.46 Billion
• 2034 Forecast Market Size: USD 920.23 Billion
• CAGR: 11.06% from 2026-2034

Market Share

• The market in North America dominated with a revenue share of 41% in 2025.
• Diguanide therapies dominated by drug class with a market share of approximately 38%.
• Adults dominated by age group with a market share of approximately 61%.

Key Regional Highlights

North America

North America led the market with a 41% share, supported by increasing prediabetes diagnosis and growing demand for preventive healthcare.

Europe

Europe accounted for 27% of the market, driven by rising awareness of metabolic health and diabetes prevention.

Asia-Pacific

Asia-Pacific held a 24% share, supported by increasing obesity rates and expanding healthcare screening programs.

U.S

The U.S. remains a key market, supported by high prevalence of prediabetes and increasing emphasis on early intervention.

Japan

Japan accounted for approximately 20% of the Asia-Pacific market, supported by advanced healthcare infrastructure and growing focus on metabolic health management.

Read More

Prediabetes Market Latest Trends

The prediabetes market is undergoing transformation through advancements in digital health, preventive therapeutics, and data-driven patient management solutions. One significant trend is the increasing use of continuous glucose monitoring systems among individuals diagnosed with prediabetes. These devices provide real-time metabolic insights, enabling earlier intervention and behavioral modification. Artificial intelligence is becoming a key component of the prediabetes industry analysis as healthcare providers leverage predictive algorithms to identify high-risk populations. Digital therapeutics platforms are increasingly being integrated into patient care pathways, offering customized exercise recommendations, dietary guidance, and remote coaching.

Download Free sample to learn more about this report.

The prediabetes market trends also indicate growing adoption of GLP-1 receptor agonists for weight management and glucose regulation among at-risk populations. Pharmaceutical innovation is expanding beyond traditional diabetes treatment toward preventive metabolic care. Corporate wellness programs are increasingly incorporating prediabetes screening and management services, creating additional opportunities for healthcare technology providers. Furthermore, telehealth services continue to improve access to preventive care in underserved regions.

Another emerging trend is the collaboration between healthcare providers and technology companies to develop integrated metabolic health ecosystems.

Prediabetes Market Dynamics

DRIVER

Rising Prevalence of Obesity and Metabolic Disorders

The increasing incidence of obesity remains one of the strongest drivers of the prediabetes market Growth. Excess body weight significantly contributes to insulin resistance, creating a large population vulnerable to prediabetes. Healthcare organizations across multiple regions are implementing large-scale screening initiatives to identify individuals at risk before diabetes develops. Growing awareness campaigns encourage routine glucose testing, further increasing diagnosis rates. Employers, insurers, and healthcare systems are prioritizing preventive healthcare programs to reduce long-term treatment burdens associated with diabetes complications. The prediabetes market Analysis indicates that lifestyle intervention programs, nutrition counseling services, and preventive pharmaceutical therapies are gaining broader acceptance. Increased healthcare spending on disease prevention and population health management further accelerates demand for prediabetes-related products and services. As metabolic health becomes a major public health priority, market participants continue expanding their offerings to address rising patient needs.

RESTRAINT

Limited Patient Adherence to Lifestyle Modification Programs

Despite increasing awareness, maintaining long-term adherence to lifestyle modification programs remains a significant restraint for the prediabetes market. Many individuals struggle to sustain dietary adjustments, regular physical activity, and weight management strategies necessary for effective prevention. Behavioral barriers often reduce the effectiveness of intervention programs and delay measurable health improvements. Healthcare providers face challenges in maintaining patient engagement over extended periods. In some regions, access to specialized preventive care services remains limited, reducing treatment effectiveness. Economic disparities may also restrict participation in structured wellness programs. Furthermore, some patients remain unaware of the seriousness of prediabetes because symptoms are often absent. These factors create obstacles for healthcare providers and pharmaceutical companies seeking widespread adoption of preventive therapies. Addressing patient compliance challenges remains a critical factor influencing long-term prediabetes market outlook.

OPPORTUNITY

Expansion of Personalized and Digital Healthcare Solutions

The emergence of personalized healthcare presents significant opportunities within the prediabetes market. Digital platforms now collect extensive health data that can be used to create customized intervention plans. Mobile applications, wearable devices, remote monitoring tools, and virtual coaching services enable continuous patient engagement. Healthcare providers increasingly utilize predictive analytics to identify individuals with elevated risk profiles and recommend targeted interventions. Pharmaceutical companies are exploring precision medicine approaches to optimize preventive therapies. Corporate wellness programs and employer-sponsored healthcare initiatives are also creating new demand channels. The integration of artificial intelligence into metabolic health management enhances patient outcomes and supports scalable preventive care models. These developments create substantial opportunities for technology providers, healthcare organizations, and pharmaceutical manufacturers participating in the evolving prediabetes industry report landscape.

CHALLENGE

Regulatory Complexity and Clinical Validation Requirements

One of the primary challenges facing the prediabetes market involves regulatory requirements and clinical validation standards for emerging therapies and digital health solutions. Regulatory authorities require extensive evidence demonstrating safety, effectiveness, and long-term benefits before approving new interventions. Clinical trials focused on prevention often require lengthy follow-up periods, increasing development costs and delaying commercialization. Digital therapeutic platforms must also demonstrate measurable health outcomes to gain widespread adoption among healthcare providers and insurers. Differences in healthcare regulations across countries create additional complexity for global market participants. Reimbursement uncertainty for preventive therapies further affects market expansion. Companies must invest heavily in research, compliance, and post-market monitoring activities to maintain competitiveness. These challenges continue influencing product development strategies throughout the prediabetes market forecast period.

Prediabetes Market Segmentation

By Drug Class

Diguanide therapies account for approximately 38% of the prediabetes market share, making them the leading therapeutic category. Their widespread adoption is supported by extensive clinical evidence demonstrating effectiveness in reducing progression toward type 2 diabetes among high-risk populations. Healthcare providers frequently incorporate diguanide-based therapies into preventive treatment plans due to their established safety profile and broad accessibility. Increasing diagnosis rates have strengthened demand for these therapies across hospitals, specialty clinics, and primary care settings. Pharmaceutical manufacturers continue evaluating expanded applications and optimized dosing strategies to improve patient outcomes.

Thiazolidinediones represent approximately 17% of the prediabetes market share. These therapies improve insulin sensitivity and play an important role in managing metabolic dysfunction among selected patient populations. Clinical studies continue evaluating their effectiveness in delaying diabetes progression and improving glucose regulation. Although utilization remains more selective compared with diguanide therapies, thiazolidinediones maintain relevance in specific treatment pathways. Healthcare providers often consider individual patient characteristics when determining suitability for this therapeutic class. Ongoing research focuses on improving safety profiles and identifying optimal patient populations.

GLP-1 agonists account for approximately 29% of the prediabetes market share and represent one of the fastest-expanding therapeutic categories. Increasing recognition of their ability to support weight management and glucose control has significantly enhanced adoption among healthcare providers. The growing prevalence of obesity has strengthened demand for therapies that address both metabolic health and body weight reduction. Clinical evidence continues demonstrating favorable outcomes among individuals at risk of developing diabetes. Pharmaceutical companies are expanding product portfolios and investing heavily in next-generation GLP-1 formulations.

DPP-4 inhibitors contribute approximately 16% of the prediabetes market share. These therapies provide an alternative approach to glucose regulation and are utilized within selected preventive treatment strategies. Their favorable tolerability profile supports continued use among patients requiring individualized therapeutic options. Ongoing clinical research evaluates the long-term role of DPP-4 inhibitors in preventing diabetes progression and supporting metabolic stability. Healthcare providers increasingly emphasize personalized treatment selection based on patient-specific characteristics. Pharmaceutical manufacturers continue exploring opportunities to enhance efficacy and expand therapeutic applications.

To know how our report can help streamline your business, Speak to Analyst

By Age Group

Children account for approximately 12% of the prediabetes market share. Rising childhood obesity rates, increased consumption of processed foods, reduced physical activity, and growing screen time have contributed to an expanding population at risk of prediabetes. Pediatric healthcare providers are increasingly implementing early screening programs to identify glucose abnormalities before progression to diabetes. Schools and public health organizations are introducing nutrition education and physical fitness initiatives to support prevention efforts. The prediabetes market research report indicates growing demand for family-centered intervention programs that encourage sustainable lifestyle changes.

Adults represent the largest application segment, accounting for approximately 61% of the prediabetes market share. This dominance is primarily attributed to sedentary lifestyles, increasing obesity prevalence, workplace stress, and dietary patterns that contribute to metabolic dysfunction. Adults are the primary target population for screening initiatives, preventive therapies, and digital health management programs. Healthcare systems increasingly emphasize early diagnosis and intervention to reduce the long-term burden associated with diabetes-related complications. Corporate wellness programs and employer-sponsored health initiatives are also expanding preventive care services for working-age populations.

The elderly segment accounts for approximately 27% of the prediabetes market share. Aging populations across developed and emerging economies have significantly increased demand for metabolic health management services. Older adults frequently experience reduced insulin sensitivity and increased susceptibility to glucose regulation disorders, creating substantial demand for preventive interventions. Healthcare providers prioritize regular monitoring, nutritional counseling, and individualized treatment strategies for elderly patients. The prediabetes market outlook indicates growing integration of remote patient monitoring systems and telehealth services to improve healthcare accessibility for aging population.

Prediabetes Market Regional Outlook

To get more information on the regional analysis of this market, Download Free sample

North America 

North America remains the leading regional market with approximately 41% share of the global prediabetes market. The region benefits from sophisticated healthcare infrastructure, widespread screening programs, advanced diagnostic capabilities, and strong awareness regarding metabolic health. Healthcare providers actively promote early identification of at-risk individuals through routine glucose testing and preventive care initiatives. The growing prevalence of obesity and sedentary lifestyles continues to expand the potential patient population requiring intervention. Digital health technologies are widely adopted across the region, supporting continuous patient monitoring and personalized treatment plans. Insurance providers increasingly recognize the long-term value of preventive care, encouraging participation in structured wellness programs. Pharmaceutical companies maintain strong research activities focused on obesity management, insulin resistance, and glucose regulation therapies. Hospitals, specialty clinics, and primary care networks collaborate extensively to improve patient outcomes through integrated care models. Employers also play a significant role by implementing workplace wellness initiatives targeting metabolic health improvement.

Europe 

Europe accounts for approximately 27% of the global prediabetes market share. The region benefits from well-established healthcare systems, broad preventive health policies, and increasing public awareness regarding chronic disease prevention. National healthcare authorities continue promoting early diagnosis initiatives to reduce long-term healthcare burdens associated with diabetes progression. The region has witnessed growing adoption of lifestyle intervention programs, nutritional counseling services, and digital health platforms designed to support metabolic health management. Healthcare providers increasingly emphasize personalized care approaches that address individual risk factors and patient behaviors. Public health campaigns encourage routine screening among populations with elevated risk profiles. Research institutions across Europe actively participate in studies exploring innovative therapeutic approaches and preventive healthcare models. Pharmaceutical companies continue expanding their presence through collaborations focused on obesity management and glucose regulation therapies. The prediabetes industry analysis highlights increasing demand for integrated healthcare solutions that combine digital technologies with traditional clinical care..

Germany prediabetes market 

Germany represents approximately 32% of the global prediabetes market share and remains one of Europe's most significant healthcare markets. The country benefits from advanced diagnostic infrastructure, strong healthcare coverage, and widespread public awareness regarding chronic disease prevention. Healthcare providers actively promote routine screening and early intervention programs targeting metabolic disorders. Research institutions continue investigating innovative approaches for glucose management and obesity prevention. Digital healthcare adoption is increasing across hospitals and outpatient facilities, supporting improved patient engagement. Growing demand for personalized treatment strategies and preventive healthcare services continues driving market development. Germany's emphasis on evidence-based medicine and proactive disease management strengthens its position within the European prediabetes market outlook.

United Kingdom prediabetes market 

The United Kingdom accounts for approximately 40% of the global prediabetes market share. National healthcare initiatives emphasize prevention, early diagnosis, and lifestyle modification to reduce progression toward type 2 diabetes. Healthcare providers increasingly utilize community-based screening programs and digital health technologies to identify at-risk individuals. Public awareness campaigns have improved understanding of metabolic health and preventive care options. Telehealth services and remote patient monitoring solutions continue expanding throughout the healthcare system. Pharmaceutical innovation and growing participation in clinical research contribute to market development. The United Kingdom remains an important contributor to European prediabetes market Growth through its strong focus on population health management and preventive medicine.

Asia-Pacific 

Asia-Pacific holds approximately 24% of the global prediabetes market share and represents one of the most dynamic regions for future growth. Rapid urbanization, changing dietary habits, increasing obesity prevalence, and expanding healthcare access contribute significantly to market expansion. Large populations in several countries create substantial opportunities for preventive healthcare providers and pharmaceutical companies. Governments throughout the region are implementing initiatives focused on early detection and chronic disease prevention. Healthcare infrastructure continues improving, enabling broader access to diagnostic services and metabolic health management programs. Rising disposable incomes support greater utilization of healthcare technologies and preventive treatment options. Digital health adoption is accelerating across Asia-Pacific, particularly through mobile health applications, wearable devices, and remote monitoring solutions. Pharmaceutical companies increasingly target regional markets with innovative therapies designed to address growing metabolic health concerns.

Japan prediabetes market 

Japan contributes approximately 20% of the global prediabetes market share. The country faces growing challenges associated with an aging population and increasing prevalence of metabolic disorders. Healthcare providers emphasize routine health examinations and preventive care strategies to identify at-risk individuals. Advanced healthcare infrastructure supports widespread access to diagnostic testing and disease management programs. Digital healthcare solutions are increasingly integrated into patient monitoring systems. Pharmaceutical innovation remains strong, with continued investment in therapies targeting glucose regulation and obesity management. Japan's commitment to preventive healthcare and technological advancement supports its position as a key contributor to the Asia-Pacific prediabetes market.

China prediabetes market 

China accounts for approximately 8% of the global prediabetes market share, making it one of the largest individual country markets. Rapid urbanization, changing lifestyles, and increasing obesity prevalence have contributed to rising rates of impaired glucose regulation. Government initiatives emphasize chronic disease prevention and improved healthcare accessibility. Healthcare providers are expanding screening programs and community-based health management services. Digital health technologies are experiencing significant adoption across urban and rural regions. Pharmaceutical companies continue increasing investments in metabolic disease research and preventive care solutions. China's large population and expanding healthcare infrastructure create substantial opportunities within the prediabetes market size and prediabetes industry analysis.

Rest of World 

The Rest of World region accounts for approximately 8% of the global prediabetes market share. This segment includes Latin America, the Middle East, and Africa, where healthcare systems are increasingly prioritizing chronic disease prevention and metabolic health management. Rising urbanization, changing dietary habits, and increasing awareness contribute to growing demand for preventive healthcare services. Governments and healthcare organizations are expanding screening programs to identify individuals at risk of diabetes progression. Improvements in healthcare infrastructure and diagnostic capabilities support broader access to metabolic health services. International collaborations and public health initiatives continue promoting education regarding healthy lifestyles and disease prevention. Digital healthcare adoption is gradually increasing throughout these regions, improving access to health information and patient monitoring tools. Pharmaceutical manufacturers are expanding market presence through partnerships and localized healthcare strategies.

List of Top Prediabetes Companies

• Novo Nordisk A/S
• Valbiotis
• RESVERLOGIX
• Caelus Health
• Scimar
• Boston Pharmaceuticals
• APHAIA PHARMA AG
• AstraZeneca
• Bristol-Myers Squibb Company
• Pfizer Inc.

Top Two Companies with Highest market share

• Novo Nordisk A/S — 24% 
• AstraZeneca — 18% (estimated share).

Investment Analysis and Opportunities

The prediabetes market report shows a strong investment case around prevention-first care, because the commercial opportunity is no longer limited to glucose testing alone. Capital is moving toward GLP-1-based therapies, oral metabolic agents, continuous glucose monitoring, remote coaching, and digital therapeutics that can slow progression before diabetes is diagnosed. The FDA’s approvals of Zepbound for chronic weight management and Wegovy for cardiovascular risk reduction in adults with obesity or overweight reinforce how weight control has become central to cardiometabolic prevention.

For investors, the most attractive prediabetes market opportunities sit in integrated platforms that combine diagnostics, adherence support, and pharmacologic intervention. Novo Nordisk’s expanding obesity and diabetes reach and AstraZeneca’s oral GLP-1 licensing activity show that large pharmaceutical firms are building longer-duration pipelines around preventive metabolic care. That creates room for device companies, digital health firms, specialty pharmacies, and contract research organizations to participate in the prediabetes industry report landscape.

New Product Development

New Product Development in the prediabetes market is centered on better efficacy, easier administration, and broader prevention use cases. Oral GLP-1 development is especially important because it can improve patient convenience versus injectable formats. AstraZeneca’s ECC5004 program is a clear example of this direction, as the company is advancing an oral once-daily GLP-1RA for obesity, type 2 diabetes, and cardiometabolic conditions. 

That matters for prediabetes because a large share of at-risk patients are more likely to adopt simpler dosing formats. Novo Nordisk is also shaping new product development through next-generation obesity and metabolic programs. In 2025, the company said it completed the REDEFINE 2 trial for CagriSema and filed for US approval of oral semaglutide 25 mg, which it says has potential to be the first oral GLP-1 treatment for obesity. Those steps matter to the prediabetes market Analysis because weight-loss efficacy and glucose control are increasingly treated as early-intervention tools.

Five Recent Developments (2023–2025)

• November 8, 2023: FDA approved Zepbound (tirzepatide) for chronic weight management in adults with obesity or overweight and at least one weight-related condition.
• November 9, 2023: AstraZeneca signed an exclusive licensing agreement with Eccogene for ECC5004, an oral GLP-1 receptor agonist targeting obesity and cardiometabolic disorders.
• November 7, 2023: Valbiotis reported positive TOTUM•63 mode-of-action results showing sustained reduction in glycated hemoglobin among individuals at risk of type 2 diabetes.
• March 8, 2024: FDA approved Wegovy for reducing the risk of major adverse cardiovascular events in adults with cardiovascular disease and obesity or overweight.
• May 6, 2025: Novo Nordisk completed the REDEFINE 2 trial for CagriSema and submitted oral semaglutide 25 mg for regulatory review in the United States.

Report Coverage 

This prediabetes market research report covers the full prevention-oriented ecosystem across screening, diagnosis support, lifestyle intervention, pharmacotherapy, digital therapeutics, and non-drug metabolic solutions. The report scope spans the prediabetes market size, prediabetes market share, prediabetes market Growth, prediabetes market trends, prediabetes market outlook, and prediabetes market opportunities across major geographies and patient groups. It also evaluates how obesity management, glucose monitoring, and cardiometabolic risk reduction are reshaping demand patterns in the broader prediabetes industry report landscape.

Request for Customization   to gain extensive market insights.

Coverage includes market segmentation by type and application, with attention to diguanides, thiazolidinediones, GLP-1 agonists, and DPP-4 inhibitors, as well as children, adults, and elderly populations. The analysis also reviews regional performance across North America, Europe, Asia-Pacific, and Rest of World, with country-level emphasis where commercialization and awareness are strongest. Competitive coverage includes leading pharmaceutical, biotech, and preventive health companies, along with pipeline activity, product innovation, and launch momentum. The report also reflects current prediabetes market insights and prediabetes market forecast drivers shaped by weight management, adherence tools, and physician-led early intervention pathways.